Tags

Type your tag names separated by a space and hit enter

Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies.
Transplant Proc. 2014 Jun; 46(5):1531-5.TP

Abstract

OBJECTIVE

We aim to evaluate the clinical efficacy of a modified busulfan and cyclophosphamide (BU/CY) conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of hematologic malignancies.

METHODS

A total of 45 patients with hematologic malignancies were treated using stem cell transplantation between March 2007 and June 2012. All the patients received a modified BU/CY conditioning regimen before transplantation. The outcomes of the patients were followed up including mortality, survival, relapse, and complications.

RESULTS

The median of follow-up duration was 527 days. All the patients who received modified BU/CY conditioning regimen achieved hematopoietic recovery successfully. Among the patients, 24 were survived without complications, 5 had relapsed hematologic malignancies, and 16 died. The median time to leucocyte engraftment was 14 days and to platelet engraftment was 12 days. Acute graft-versus-host disease (aGVHD; grades I-IV) occurred in 15 patients (30%). The cumulative incidence of grades I aGVHD was 22.2% (10 patients), grades II was 6.7% (3 patients), and grades III-IV was 4.4% (2 patients). Among 40 appreciable patients, 8 (20%) developed chronic GVHD. The incidence rate of hemorrhagic cystitis and veno-occlusive disease were 15.5% and 2.2%, respectively.

CONCLUSIONS

The modified BU/CY conditioning regimen for allo-HSCT is effective and safe for the treatment of hematologic malignancies.

Authors+Show Affiliations

Department of Hematology and Oncology, Children's Hospital of Zhengzhou, Zhengzhou, China.Department of Internal Medicine, The No.Three People's Hospital of Henan, Henan, China.Department of Hematology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Electronic address: dingmingwan@hotmail.com.Department of Hematology and Oncology, Children's Hospital of Zhengzhou, Zhengzhou, China. Electronic address: xyxf03@126.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24935325

Citation

Zhao, X F., et al. "Modified Busulfan and Cyclophosphamide Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Patients With Hematologic Malignancies." Transplantation Proceedings, vol. 46, no. 5, 2014, pp. 1531-5.
Zhao XF, Mao XF, Wan DM, et al. Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies. Transplant Proc. 2014;46(5):1531-5.
Zhao, X. F., Mao, X. F., Wan, D. M., & Liu, W. (2014). Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies. Transplantation Proceedings, 46(5), 1531-5. https://doi.org/10.1016/j.transproceed.2014.02.023
Zhao XF, et al. Modified Busulfan and Cyclophosphamide Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of Patients With Hematologic Malignancies. Transplant Proc. 2014;46(5):1531-5. PubMed PMID: 24935325.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Modified busulfan and cyclophosphamide conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of patients with hematologic malignancies. AU - Zhao,X F, AU - Mao,X F, AU - Wan,D M, AU - Liu,W, PY - 2013/09/12/received PY - 2014/02/07/revised PY - 2014/02/27/accepted PY - 2014/6/18/entrez PY - 2014/6/18/pubmed PY - 2015/2/27/medline SP - 1531 EP - 5 JF - Transplantation proceedings JO - Transplant Proc VL - 46 IS - 5 N2 - OBJECTIVE: We aim to evaluate the clinical efficacy of a modified busulfan and cyclophosphamide (BU/CY) conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the treatment of hematologic malignancies. METHODS: A total of 45 patients with hematologic malignancies were treated using stem cell transplantation between March 2007 and June 2012. All the patients received a modified BU/CY conditioning regimen before transplantation. The outcomes of the patients were followed up including mortality, survival, relapse, and complications. RESULTS: The median of follow-up duration was 527 days. All the patients who received modified BU/CY conditioning regimen achieved hematopoietic recovery successfully. Among the patients, 24 were survived without complications, 5 had relapsed hematologic malignancies, and 16 died. The median time to leucocyte engraftment was 14 days and to platelet engraftment was 12 days. Acute graft-versus-host disease (aGVHD; grades I-IV) occurred in 15 patients (30%). The cumulative incidence of grades I aGVHD was 22.2% (10 patients), grades II was 6.7% (3 patients), and grades III-IV was 4.4% (2 patients). Among 40 appreciable patients, 8 (20%) developed chronic GVHD. The incidence rate of hemorrhagic cystitis and veno-occlusive disease were 15.5% and 2.2%, respectively. CONCLUSIONS: The modified BU/CY conditioning regimen for allo-HSCT is effective and safe for the treatment of hematologic malignancies. SN - 1873-2623 UR - https://www.unboundmedicine.com/medline/citation/24935325/Modified_busulfan_and_cyclophosphamide_conditioning_regimen_for_allogeneic_hematopoietic_stem_cell_transplantation_in_the_treatment_of_patients_with_hematologic_malignancies_ DB - PRIME DP - Unbound Medicine ER -